|
| Press Releases |
|
 |
|
| Wednesday, September 5, 2018 |
|
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
| Friday, July 27, 2018 |
|
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
| Friday, June 22, 2018 |
|
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, June 6, 2018 |
|
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
| Friday, May 4, 2018 |
|
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
| Wednesday, April 18, 2018 |
|
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
| Wednesday, April 11, 2018 |
|
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
| Friday, March 30, 2018 |
|
|
Nanobiotix 2017 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
| Monday, January 22, 2018 |
|
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
| Thursday, January 11, 2018 |
|
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
JDE Peet's 正式启用 OMP 的 Unison Planning(TM) 系统，大规模提升供应链价值
Apr 1, 2026 21:50 HKT/SGT
|
|
|
JDE Peet's Goes Live with OMP's Unison Planning(TM), Accelerating Supply Chain Value at Scale
Apr 1, 2026 21:50 HKT/SGT
|
|
|
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Apr 1, 2026 21:00: JST
|
|
|
GMG Verified by Advanced Carbons Council & Successful ISO9001 Audit
Apr 1, 2026 21:00 HKT/SGT
|
|
|
Datavault AI 再度現身馬阿拉戈，出席專屬投資者論壇
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Datavault AI 再度亮相马阿拉戈，参加独家投资者论坛
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Four leading spring tech fairs will take place in April, featuring over 3,700 exhibitors
Apr 1, 2026 19:52: JST
|
|
|
Four leading spring tech fairs will take place in April, featuring over 3,700 exhibitors
Apr 1, 2026 18:52 HKT/SGT
|
|
|
True IDC Pushes "Security Economy", Breaking Ground on Mega Data Center in EEC with 77-Billion-Baht BOI Investment, Cementing Thailand's No. 1 Position
Apr 1, 2026 18:50 HKT/SGT
|
|
|
China Risun (01907.HK) Reports Strong 37.7% Net Profit Surge in 2025 Amid Industry Challenges
Apr 1, 2026 18:07 HKT/SGT
|
|
|
中國旭陽集團（01907.HK）積極面對行業變化 2025年淨利逆勢增長37.7%
Apr 1, 2026 17:50 HKT/SGT
|
|
|
中国旭阳集团（01907.HK）积极面对行业变化 2025年净利逆势增长37.7%
Apr 1, 2026 17:42 HKT/SGT
|
|
|
CTF Life Collaborates with the HKMC to Refer the Policy Reverse Mortgage Programme and the Reverse Mortgage Programme
Apr 1, 2026 16:20 HKT/SGT
|
|
|
周大福人壽與香港按揭證券有限公司合作
Apr 1, 2026 16:02 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
